<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-6N0CGETH</identifier><date>2020</date><creator>Janić, Miodrag</creator><creator>Lunder, Mojca</creator><relation>documents/doc/6/URN_NBN_SI_doc-6N0CGETH_001.pdf</relation><relation>documents/doc/6/URN_NBN_SI_doc-6N0CGETH_001.txt</relation><format format_type="issue">2</format><format format_type="volume">72</format><format format_type="type">article</format><format format_type="extent">str. 115-124</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">65637891</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-6N0CGETH</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">diabetična dislipidemija</subject><subject language_type_id="slv">dislipidemija</subject><subject language_type_id="slv">sladkorna bolezen</subject><subject language_type_id="slv">zdravljenje</subject><title>Diabetic dyslipidemia</title><title>Diabetična dislipidemija</title><title>from pathogenesis to the latest treatment options</title><title>od patogeneze do najnovejših možnosti zdravljenja</title></Record>